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Revealing mechanisms for SH2 domain mediated regulation of
the protein tyrosine phosphatase SHP-2
David Barford1* and Benjamin G Neel2
The crystal structure of the protein tyrosine phosphatase
SHP-2 reveals the mechanism of auto-inhibition of
phosphatase activity by its SH2 domains. Phosphotyrosine
peptide stimulation of the phosphatase activity, resulting
from peptide binding to the N-terminal SH2 domain, is
linked to conformational changes within the protein,
including an unprecedented allosteric transition of the
N-terminal SH2 domain.
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Intracellular signalling is mediated by the modulation of
protein–protein and protein–lipid interactions associated
with the assembly of multiprotein complexes [1]. Such
processes function not only to alter the conformation of
signalling molecules but also to recruit them to their cellu-
lar targets. An important example of this concept is the
activation of cell surface receptors by extracellular ligands,
including hormones, growth factors, cytokines and anti-
gens, that results in receptor tyrosine phosphorylation by
either integral or associated protein tyrosine kinases.
Tyrosine phosphorylation initiates downstream signalling
pathways by creating sequence-specific recognition sites
for Src homology 2 (SH2) and phosphotyrosine-binding
(PTB) domains and hence assists the assembly of multi-
protein complexes.
Signalling molecules are formed from relatively few
protein families, with diversity of structure and function
being generated by the shuffling of protein modules and
domains endowed with specific functions: for example
SH2 and SH3 domains and protein kinase and phosphatase
activities [2]. In addition to recruiting proteins to activated
receptors, SH2 and SH3 domains may also autoregulate
enzyme catalytic activity. In the absence of a stimulatory
phosphotyrosine (pTyr) signal, most SH2 domain contain-
ing enzymes, for example the protein tyrosine kinases Src,
ZAP-70 and Syk, SHP protein tyrosine phosphatases
(mammalian SHP-1, SHP-2 and Drosophila corkscrew),
phosphatidylinositol-3-kinase and phospholipase C- g 1, are
catalytically inactive as a consequence of SH2 domain
mediated auto-inhibition. These proteins are reminiscent
of allosterically regulated metabolic enzymes, existing in
dynamic equilibrium between activated and inactive
states. In this instance, the allosteric activator is a tyrosine
phosphorylated receptor that stabilises the activated con-
formation of the enzyme.
The crystal and NMR structures of SH2-domain–
phosphopeptide complexes have demonstrated the
molecular mechanisms underlying sequence specificity
for pTyr peptides [3]. More recently, the structures of
Src and hematopoietic cell kinase (Hck) revealed the
mechanism of regulation of the protein tyrosine kinase
(PTK) domain of these enzymes by their N-terminal
SH2 and SH3 domains [4,5]. Now in a recent paper,
Shoelson and colleagues report the crystal structure of
the SH2 domain containing protein tyrosine phosphatase
(PTP), SHP-2 [6]. This work presents the first structure
of an intact double SH2 domain containing protein,
revealing the mechanisms of regulation of phosphatase
activity by the SH2 domains. SH2 domain mediated
regulation of phosphatase activity of SHP-2 contrasts
strikingly with the mode of SH2 and SH3 domain medi-
ated regulation of Src and Hck. Taken together, the
SHP-2 and Src family protein kinase structures provide a
framework for understanding the regulation of other SH2
domain containing proteins.
Higher eukaryotes encode two SH2 domain containing
PTPs, SHP-1 and SHP-2, which although highly related
in structure (sharing 60% overall sequence identity)
display distinct tissue distributions and biological func-
tions [7]. Both SHP-1 and SHP-2 associate with activated
receptors in vivo and in vitro via specific SH2 domain
mediated recognition of pTyr residues [8,9]. SHP-1 is
largely restricted to cells of hematopoietic origin and
epithelial cells, whereas SHP-2 is expressed in all cell
types. The physiological function of SHP-1 is to nega-
tively regulate several different types of signal transduc-
tion pathways, including those associated with cytokine
receptors, immune recognition receptors (such as the B
and T cell antigen receptors) and certain tyrosine kinases.
The precise targets of SHP-1 are controversial, but may
include the receptors themselves, receptor-associated
PTKs, such as Janus kinases, and/or other tyrosyl phos-
phorylated signalling components.
In contrast to SHP-1, SHP-2 positively regulates signal
transduction events from activated receptor protein
tyrosine kinases (RTKs) including those for growth
factors, hormones and cytokines. The precise targets of
SHP-2 are also unknown, but may include daughter of
sevenless (DOS)-like molecules or the adhesion
molecules SIRPs (signal regulation proteins). SHP-2
performs essential roles in developmental processes: the
enzyme is required for fibroblast growth factor (FGF)-
induced mesoderm patterning and completion of
gastrulation in Xenopus [10,11] and mouse embryos [12].
The Drosophila homologue of SHP-2, corkscrew [13],
was initially found to be required for signalling from the
RTK torso, which directs early embryonic head and tail
development. Subsequent work has established that
corkscrew is required for other RTKs-triggered
pathways, including those for sevenless [14], breathless
and Der [15].
Like other PTP and SH2 domain containing proteins,
SHP-1 and SHP-2 are constructed on a modular basis.
The proteins contain two SH2 domains at the N terminus
(N-SH2 and C-SH2, where N-SH2 is closest to the N
terminus) followed by a PTP domain. The C-terminal 66
amino acid residues of SHP-2 contain sites of tyrosine
phosphorylation and a proline-rich domain that may be
capable of binding to SH3 or WW domain containing
proteins. Phosphorylation of these tyrosine residues by
activated PTKs creates binding sites for the adapter
molecule Grb-2, suggesting a potential role for SHP-2 as
an adapter protein within certain signalling pathways.
Earlier studies established that both SHP-1 and SHP-2
are essentially inactive under basal conditions, resulting
from auto-inhibition of the PTP domain by the N-SH2
domain. The isolated phosphatase domain retains full
catalytic activity [16] that is suppressed by addition of the
SH2 domains [17]. Catalytic activity of both SHPs is
increased on engagement of pTyr peptides by the SH2
domains. Singly phosphorylated peptides increase
activity tenfold [9,18], whereas doubly phosphorylated
peptides, which engage both SH2 domains simultane-
ously, cause a more dramatic 100-fold activation at greatly
reduced phosphopeptide concentrations [19,20]. Specific
inactivation of the pTyr recognition sites of the N-SH2
and C-SH2 domains, achieved by mutating an invariant
phosphate-coordinating arginine residue (Arg b B5) in
both SHP-2 [9,19] and SHP-1 [21], or truncation of either
the N-SH2 or C-SH2 domains of SHP-1 [21,22], revealed
that the N-SH2 domain is responsible for the inhibition
of PTP activity. Engagement of pTyr peptides by this
domain contributes to almost all the pTyr peptide
induced enzyme activation, with virtually no contribution
from the C-SH2 domain. These results probably explain
why the N-SH2 domain plays a more important role than
the C-SH2 domain in SHP-2-mediated FGF signalling in
Xenopus [11]. Optimal signalling, however, requires both
SH2 domains.
An understanding of the molecular basis for the auto-
inhibition of the PTP domain of SHP-2 by its SH2
domains and for the stimulation of catalytic activity by
pTyr peptides has been provided by the crystal structure
of the enzyme determined by Shoelson and colleagues [6].
The structure corresponds to the full-length protein with a
truncation of the C-terminal 66 residues. This form of
SHP-2 is activated by phosphopeptides in an identical
manner to the wild-type enzyme [6]. The mechanism of
inhibition of the PTP domain is close to that predicted
previously. However, the nature of the allosteric confor-
mational changes which lead to activation of the PTP
domain by phosphopeptide engagement of the N-SH2
domain is a surprise, and illustrates a previously unrecog-
nised structural transition within an SH2 domain.
The inactive form of SHP-2 adopts a closed conformation
with the N-SH2 domain interacting extensively with the
PTP domain, directly blocking the phosphatase catalytic
site (Figure 1). The C-SH2 domain is linked to the neigh-
bouring N-SH2 and PTP domains but does not share a
significant interface with either of these two domains.
Unexpectedly, the pTyr peptide binding sites of both
SH2 domains are exposed to solvent and do not form part
of the interdomain recognition surfaces. The architecture
of the SH2 and PTP domains of SHP-2 are very similar to
those of other SH2 and PTP domains determined previ-
ously [3,23,24]. The sequences of the PTP domains of the
SHPs are more closely related to receptor PTPs (RPTPs)
than to other cytosolic PTPs. This relationship is reflected
in the three-dimensional structure of the PTP domain of
SHP-2. The structure most closely resembles domain 1 of
RPTPa and RPTPm [25,26], possessing an additional two-
stranded b sheet which is absent from the cytosolic PTPs,
PTP1B and Yersinia YopH (Figure 1).
PTPs catalyse dephosphorylation reactions by means of a
thiol–phosphate enzyme intermediate involving an invari-
ant cysteine residue. This catalytic cysteine residue is
located at the base of a catalytic site cleft (9 Å in depth)
that determines specificity for pTyr-containing peptides
and precludes binding of shorter pSer and pThr
sidechains [27]. The cysteine residue is incorporated
within a phosphate-binding cradle formed by the PTP
signature motif sequence and composed of mainchain
amide groups and the sidechain of an invariant arginine
residue. Binding of a pTyr residue to the catalytic site is
accompanied by closure of a surface loop, the WPD loop,
which brings an essential catalytic aspartic acid residue
within hydrogen-bonding distance of the scissile phenolic
oxygen atom of the pTyr substrate, creating a catalytically
competent enzyme conformation. The phenyl ring of the
pTyr residue forms hydrophobic interactions with a tyro-
sine sidechain of the pTyr-recognition loop and with
residues of the WPD loop. A fourth catalytic site loop, the
Q loop, containing an invariant glutamine residue that
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coordinates the nucleophilic water molecule during the
thiolysis reaction [28], is situated adjacent to the pTyr-
recognition and WPD loops (Figures 1 and 2).
In the inactive form of SHP-2, the D¢ E loop and adjacent
D¢ and E b strands of the N-SH2 domain insert deep into
the catalytic site cleft of the PTP domain forming interac-
tions with residues of the catalytic loops (i.e. the phosphate-
binding cradle, the pTyr-recognition loop and the Q loop;
Figures 1 and 2). These interactions inhibit enzyme activity
for two reasons. Firstly, Asp61 and Tyr62 of the D¢ E loop of
N-SH2 mimic the interactions of a pTyr substrate with the
catalytic domain and sterically block access of phospho-
peptides to the catalytic site. The sidechain of Asp61 forms
water-mediated hydrogen bonds to the mainchain groups of
the pTyr-binding cradle and the sidechain of the catalytic
cysteine residue, whereas the sidechain of Tyr62 interacts
with Tyr279 (equivalent to Tyr46 of PTP1B) within the
pTyr-recognition loop. Secondly, the N-SH2 domain inacti-
vates the phosphatase by restraining the WPD loop in the
open, catalytically inactive conformation.
Blockade of the catalytic site may be a common mecha-
nism of enzymatic inhibition of PTPs. Bilwes et al.,
observed that the membrane proximal PTP domain of the
receptor-like phosphatase, RPTPa , crystallised as a dimer
whereby the catalytic site of each subunit was sterically
blocked by a wedge connecting two helices, a 1 ¢ and a 2 ¢,
within a helix-turn-helix segment from the opposite
subunit of the dimer. Residues of this wedge directly
interact with equivalent catalytic site residues that are part
of the phosphopeptide-binding site of PTP1B and restrain
the WPD loop in the inactive conformation [25]. These
structural data have been used to explain the signalling
properties of a chimaeric molecule consisting of the extra-
cellular domain of the epidermal growth factor (EGF)
receptor and the transmembrane and cytosolic portion of
the RPTP CD45 [29], although this model is unlikely to
be valid for all RPTPs [26]. This chimaera restores sig-
nalling within CD45 deficient T cells only in the absence
of EGF. It was proposed that in the presence of growth
factor, dimerisation of the chimaera is induced with result-
ing inhibition of CD45 phosphatase activity [25].
Stimulation of the PTP activity of SHP-2 by association of
the N-SH2 domain with a phosphopeptide results from an
unexpected allosteric transition within the SH2 domain.
Although the phosphopeptide-recognition site of the
N-SH2 domain is distinct and non-overlapping with the
site of interaction between the SH2 domain and the PTP
domain, the two sites are linked via an allosteric change
between two distinct SH2 domain conformations: an
active (A) peptide-bound state and an inactive (I) PTP
domain interaction state (Figure 3). Compared with the
structures of the isolated N-SH2 domain, both in the
absence of and in complex with peptide, the residues of
N-SH2 that interact with the PTP domain of SHP-2 (i.e.
residues of the secondary b sheet b D¢ , b E and b F) and
helix a B, have undergone a concerted conformational
change of approximately 2 Å (Figure 3) [20,30]. Motion of
the a B helix links the PTP-binding site of N-SH2 to a
conformational change of the EF loop, which together
with the adjacent BG loop forms the SH2 domain binding
site for phosphopeptide residues C-terminal to the pTyr
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Figure 1
The overall structure of SHP-2 [6]. The N-
SH2, C-SH2 and protein tyrosine
phosphatase (PTP) domains are shown in
yellow, green and cyan, respectively. The
catalytic site loops of the PTP domain are
indicated: the PTP loop is in red; the pTyr-
recognition loop is in green; the WPD loop is
in yellow; and the Q loop is in white. The
position of the N-SH2 domain D¢ E loop, which
inserts into the PTP domain catalytic site, and
sidechain of the catalytic cysteine residue are
also indicated together with the SH2 domain
EF and BG loops. (The figure was produced
using MOLSCRIPT [33].)
residue. The two conformations of the N-SH2 domain
possess two mutually exclusive properties. The I confor-
mation is competent to bind to the PTP domain, sharing
surface complementarity with the catalytic site, but con-
tains a blocked phosphopeptide-binding site as a result of
the motion of the EF loop towards the BG loop. In con-
trast, the phosphopeptide-binding state (A) possesses a
disrupted PTP domain recognition surface. The allosteric
transition from the I to the A state of the N-SH2 domain is
regulated by stimulatory pTyr peptides that bind to the
N-SH2 domain. A conformational transition of this nature
within SH2 domains has not been previously observed.
The authors suggest that the presence of an alanine
residue at position a B4 of the B helix, unique to the
N-SH2 domains of SHPs, facilitates motion of the a B
helix relative to the central b sheet of the SH2 domain.
Within over 70 other SH2 domains, more bulky valine,
isoleucine or leucine residues occur at this position, which
create a more rigid interface between the a B helix and the
b sheet [6]. The residues involved in mediating the inhi-
bition of the PTP domain of SHP-2 are conserved within
SHP-1 and corkscrew, suggesting that these enzymes are
subject to the same regulatory mechanisms.
The C-SH2 domain forms few interactions with the PTP
and N-SH2 domains and the peptide-binding site is
remote from any interdomain interface. Moreover, the
conformation of the C-SH2 domain within SHP-2 is
similar to its conformation within the crystal structure of
the isolated N-SH2 and C-SH2 domains with bound
peptide [20]. These observations are largely consistent
with data indicating that phosphopeptide binding to the
C-SH2 domain alone has little to no stimulatory affect on
PTP activity in SHP-2 [9,19] and SHP-1 [21]. One obser-
vation not fully explained by the crystal structure of
SHP-2 is the tenfold higher activation of SHPs by doubly
phosphorylated peptides relative to singly phosphorylated
peptides [19]. The structure would predict that as the
C-SH2 domain does not contribute to inhibition of the
PTP domain, at concentrations of singly phosphorylated
peptides sufficiently high to saturate the N-SH2 domain
the activity of SHPs should be equivalent to that stimu-
lated by doubly phosphorylated peptides. One explana-
tion as to why this is not the case may be that inhibition of
the PTP domain occurs at the peptide concentrations
required to saturate the N-SH2 domain. However, this
would not explain the findings that both SHP-2 with
mutations in the C-SH2 domain Arg b B5 residue [9], and
SHP-1 lacking the entire C-SH2 domain [21], were stimu-
lated to a lower extent by certain singly phosphorylated
peptides than the wild-type enzyme. An alternative expla-
nation, that peptide engagement to the C-SH2 domain
provides some stimulatory response, therefore seems
likely. Consistent with this idea are the properties of
mutant SHP-2, with N-SH2 domain Arg b B5 substitu-
tions, that can be activated by pTyr peptides [9,19]. It is
possible that the C-terminal 66 residues, missing from the
SHP-2 crystal structure, play a role in the C-SH2 domain
mediated regulation of PTP activity.
A recent report demonstrated that a characteristic of
tandem SH2 domains is an increased selectivity for phos-
phopeptides compared with single SH2 domains. More-
over, the relative arrangement of SH2 domains within
tandem repeats can force spatial restraints on the recogni-
tion of phosphopeptides [31]. Thus, the C-SH2 domain
within SHPs probably performs numerous functions.
Firstly, this domain allows recruitment of SHP-2 to pTyr
sites within activated receptors and, as a result of coopera-
tivity effects, increases the effective binding affinity of the
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Figure 2
Mechanism of inhibition of the protein tyrosine phosphatase (PTP)
domain of SHP-2 by the N-SH2 domain. (a) The structure of the
catalytic site of the PTP domain of SHP-2 [6] and comparison with (b)
the structure of a phosphotyrosine peptide (in yellow) bound at the
catalytic site of PTP1B [27]. Residues of the N-SH2 domain D¢ E loop
of SHP-2 occupy a similar position to the peptide bound to the PTP1B
catalytic site. A water molecule bridging the sidechains of Cys459 and
Asp61 is shown as an orange sphere. The colours of the domains and
catalytic site loops are as described in Figure 1.
N-SH2 domain for pTyr residues, hence compensating for
the energetic costs of conformational changes and disrup-
tion of protein–protein interactions. Secondly, tandem
SH2 domains provide increased specificity in signal trans-
duction pathways [20,31].
The structural data of Hof et al., [6] also provide insights
into possible models for the in vivo properties of SHPs.
For example, it is likely that engagement of pTyr
sequences by the C-SH2 domain alone could recruit SHPs
to cell surface receptors without concomitant phosphatase
activation. Regulation of phosphatase activity would
depend on the state of phosphorylation of tyrosine
residues within sequences recognised by the N-SH2
domain. In addition, C-SH2 domain directed recruitment
of SHP-2 could allow SHP-2 to act as an adapter molecule,
independently of its phosphatase activity.
Similarly to the role of the SH2 domains of SHPs, the
N-terminal SH3 and SH2 domains of Src family PTKs
autoregulate protein kinase activity. The auto-inhibition
of these kinases is relieved by engagement of peptide
sequences of activating proteins to the respective binding
sites on the SH3 and SH2 domains [32]. A distinct means
of activation results from the dephosphorylation of the C-
terminal pTyr residue (pTyr527). Comparison of SHP-2
and Src family PTK structures reveals striking and intrigu-
ing differences in the molecular mechanisms underlying
the regulation of these proteins. Within the inactive Src
PTK structures [4,5], the SH2 and SH3 domains are
sequestered by intramolecular interactions on the opposite
side of the kinase domain to the catalytic site; the SH2
domain interacts with pTyr527 and the SH3 domain inter-
acts with a peptide sequence linking the SH2 and protein
kinase domains. These intramolecular interactions sta-
bilise a closed conformation of the kinase domain leading
to disruption of catalytic site residues and loss of enzyme
activity. Full activation of Src PTKs requires the release of
the intramolecular SH2 and SH3 domain interactions and
phosphorylation of Tyr416 of the kinase domain activation
segment. This phosphorylation leads to conformational
changes similar to those observed for the activation of
cyclin-dependent protein kinases by cyclin association and
kinase domain phosphorylation. Together, the structures
of SHP-2 and Src family PTKs shed new light on the role
of SH2 domains in regulating intracellular signalling.
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